Blood cancers

Venetoclax shows promising activity in patients with RRMM

Venetoclax shows encouraging efficacy in heavily-treated patients with relapsed/refractory MM, according to a review of data from patients treated outside of clinical trials. The BCL-2 inhibitor is particularly promising in the  t(11;14) patient-population according to a study of 56 patients with relapsed and/or refractory MM, led by Dr  Hasib Sidiqi of the Haematology Department, Fiona ...

Already a member?

Login to keep reading.

© 2021 the limbic